Insights from a rare myeloproliferative neoplasm with coexisting BCR-ABL1 fusion gene, CALR, and TET2 mutations treated with nilotinib and ruxolitinib.

导出 LinkOut

翻译打印收藏纠错

作者： Li,Huo ^[1] ; Jundan,Xie ^[1] ; Qian,Wang ^[1] ; Hongjie,Shen ^[1] ; Zixuan,Ding ^[1] ; Lijun,Wen ^[1] ; Zhao,Zeng ^[1] ; Yi,Xu ^[1] ; Changgeng,Ruan ^[2] ; Suning,Chen ^[2] ; Mengxing,Xue ^[1]

作者单位： Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, NHC Key Laboratory of Thrombosis and Hemostasis The First Affiliated Hospital of Soochow University Suzhou China. ^[1] Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, NHC Key Laboratory of Thrombosis and Hemostasis The First Affiliated Hospital of Soochow University Suzhou China.;Collaborative Innovation Center of Hematology Soochow University Suzhou China. ^[2]

关键词 BCR‐ABL1 fusion gene CALR mutation myeloproliferative neoplasms nilotinib ruxolitinib

DOI 10.1002/ccr3.6801

PMID 36703773

发布时间 2024-09-11

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Clinical case reports

2023年11卷1期

e6801页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Insights from a rare myeloproliferative neoplasm with coexisting <i>BCR-ABL1</i> fusion gene, <i>CALR,</i> and <i>TET2</i> mutations treated with nilotinib and ruxolitinib.

Clinical case reports

相似文献

Clinical case reports

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Insights from a rare myeloproliferative neoplasm with coexisting <i>BCR-ABL1</i> fusion gene, <i>CALR,</i> and <i>TET2</i> mutations treated with nilotinib and ruxolitinib.

Clinical case reports

相似文献

Clinical case reports

相关期刊

检索历史清除